Thoratec's heart pump shows positive trial results

08/29/2007 | Washington Post, The

A clinical trial revealed that a continuous flow pump helped keep 75% of 133 patients with end-stage heart failure alive for at least six months, and 68% alive for 12 months. Researchers found no increased incidence of blood clotting among patients after implanting Thoratec Corp.'s Heart Mate II, which will be reviewed by an FDA panel for approval as a bridge to heart transplants. "The design is completely different from existing assist devices," the lead researcher said.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care